Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 2Head and Neck Neoplasms 2Carcinoma 2Sexual Dysfunction, Physiological 1Pyridoxine-dependent epilepsy 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Radiotherapy 2Vitamin D 1Testosterone 1Tadalafil 1Radiosurgery 1Pilocarpine 1Phenylephrine 1Lidocaine 1Hormonal Contraception 1Estradiol 1Drug Therapy 1Dehydroepiandrosterone 1Arginine 1ArginMax 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sexual Dysfunction, Physiological × Tadalafil × Clear all
NCT00931528 2018-02-14

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Radiation Therapy Oncology Group

Phase 3 Completed
242 enrolled 13 charts
GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡